Drug-eluting stents for the treatment of in-stent restenosis: a clinical review.

Ron Waksman, Andrew E Ajani, Bryan P Y Yan

Journal: Cardiovascular revascularization medicine : including molecular interventions 2006;6(1):38-43

PMID: 16263355

Full Text on Elsevier Science View on PubMed

Abstract

Treatment of in-stent restenosis (ISR) remains problematic despite the widespread application of drug-eluting stents (DES). Challenging lesion cohorts such as diffuse ISR and restenosis after failed intracoronary radiation therapy (IRT) maybe best treated with DES. The overall benefit of DES appears inferior to their utility in treating de novo coronary lesions. Randomised trials comparing DES and IRT will soon be available to determine the optimal therapy for ISR. The challenge to treat ISR in the DES era is the next frontier of interventional cardiology.

Address: Department of Cardiology, Royal Melbourne Hospital, Melbourne, Australia.

DOI: 10.1016/j.carrev.2005.04.003

Link outs

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S1553...

MeSH Terms: Antibiotics, Antineoplastic, Antineoplastic Agents, Phytogenic, Coated Materials, Biocompatible, Coronary Restenosis, Humans, Paclitaxel, Sirolimus, Stents